Françoise Heymans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Françoise Heymans has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
France Massicot
Université Paris Descartes, UFR Pharmacie 4, avenue de l’Observatoire, 75006 Paris, France
5 shared publicationsChang-Zhi Dong
Unité de Pharmacochimie Moléculaire et Systèmes Membranaires (EA2381), Laboratoire de Pharmacochimie Moléculaire, Université Paris 7-Denis Diderot , Bâtiment Lavoisier, Paris , France
3 shared publicationsDarina Aoun
Laboratoire ITODYS, équipe Pharmacochimie Moléculaire, Université Paris Diderot, 15 rue de Baïf, 75205 Paris Cedex 13, France
3 shared publicationsAazdine Lamouri
Unité de Pharmacochimie Moléculaire et Systèmes Membranaires (EA 2381), Université Paris 7 – Denis Diderot, case 7066, 2 Place Jussieu, 75251 Paris Cedex 05, France, Fax: +33‐144275641
2 shared publicationsFrançois Chau
Laboratoire ITODYS, équipe Pharmacochimie Moléculaire, Université Paris Diderot, 15 rue de Baïf, 75205 Paris Cedex 13, France
2 shared publications- Hong-Zhuan Chen
Shuguang Lab of Future Health, Shanghai Frontiers Science Center of TCM Chemical Biology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications
Latest Publications
- 15 May 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 18 (10) , 3588-3600
Design of new potent and selective secretory phospholipase A2 inhibitors. 6-Synthesis, structure–activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives
- 15 May 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 18 (10) , 3588-3600
Design of new potent and selective secretory phospholipase A2 inhibitors. 6-Synthesis, structure–activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives
- Open Access
- 22 May 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 12 (10) , 1409-1419
Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice
Amyloid-β-induced neuroinflammation plays a central role in the extensive loss of cholinergic neurons and cognitive decline in Alzheimer's disease. T
- 22 May 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 12 (10) , 1409-1419
Open AccessNovel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice
Amyloid-β-induced neuroinflammation plays a central role in the extensive loss of cholinergic neurons and cognitive decline in Alzheimer's disease. T
- 18 December 2007
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2008 (2) , 299-307
Synthesis of New Trisubstituted 4‐Aminopiperidines as PAF‐Receptor Antagonists
- 18 December 2007
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2008 (2) , 299-307
Synthesis of New Trisubstituted 4‐Aminopiperidines as PAF‐Receptor Antagonists
- Open Access
- 23 January 2006
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 10 (01) , 21-29
Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity
The key pathophysiological mechanisms in Alzheimer's disease involve the selective loss of cholinergic neurons and pro-inflammatory mediator-related
- 23 January 2006
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 10 (01) , 21-29
Open AccessPharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity
The key pathophysiological mechanisms in Alzheimer's disease involve the selective loss of cholinergic neurons and pro-inflammatory mediator-related
- 20 June 2005
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2005 (13) , 2747-2757
Molecular Modeling, Design, and Synthesis of Less Lipophilic Derivatives of 3‐(4‐Tetradecyloxybenzyl)‐4H‐1,2,4‐oxadiazol‐5‐one (PMS1062) Specific for Group II Enzyme
3‐(4‐Tetradecyloxybenzyl)‐4H‐1,2,4‐oxadiazol‐5‐one (PMS1062 or I) can probably act as a PLA2‐II inhibitor on the acute inflammation model, but its highly lipophilic character could prevent it from being biodistributed effectively. In this work, based on a molecular modeling study, we have proposed a model that may provide compounds retaining both anti‐PLA2 activity and specificity while becoming active per os. Moreover, molecular dynamics and energy minimization enabled us to characterize the lowest‐energy complexes of each derivative. Energy balances taking account of the conformational energy changes of both partners, along with the drug–protein interaction, were performed, and were further completed by single‐point computations of the contributions of solvation/desolvation to the binding. The ordering of the resulting energy balances was found to be fully consistent with the experimentally ascertained ordering of affinities inferred from the IC50 values. The essential role of an indole group partaking in cation–π and hydrophobic interactions, together with the CaII‐chelating oxadiazolone ring, was highlighted for the best binding compound. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)
- 20 June 2005
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2005 (13) , 2747-2757
Molecular Modeling, Design, and Synthesis of Less Lipophilic Derivatives of 3‐(4‐Tetradecyloxybenzyl)‐4H‐1,2,4‐oxadiazol‐5‐one (PMS1062) Specific for Group II Enzyme
3‐(4‐Tetradecyloxybenzyl)‐4H‐1,2,4‐oxadiazol‐5‐one (PMS1062 or I) can probably act as a PLA2‐II inhibitor on the acute inflammation model, but its highly lipophilic character could prevent it from being biodistributed effectively. In this work, based on a molecular modeling study, we have proposed a model that may provide compounds retaining both anti‐PLA2 activity and specificity while becoming active per os. Moreover, molecular dynamics and energy minimization enabled us to characterize the lowest‐energy complexes of each derivative. Energy balances taking account of the conformational energy changes of both partners, along with the drug–protein interaction, were performed, and were further completed by single‐point computations of the contributions of solvation/desolvation to the binding. The ordering of the resulting energy balances was found to be fully consistent with the experimentally ascertained ordering of affinities inferred from the IC50 values. The essential role of an indole group partaking in cation–π and hydrophobic interactions, together with the CaII‐chelating oxadiazolone ring, was highlighted for the best binding compound. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)